TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07632573: A Phase I Clinical Study to Evaluate the Safety/Tolerability, Pharmacokinetics/Pharmacodynamics of BDHK-2009 Tablets in Healthy Adult Participants: a Randomized, Double-blind, Placebo-controlled, Single-dose/Multiple-dos

Sponsor: Benethera (Shaoxing) Biotechnology Co., Ltd. · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 68 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,507,200

Rescue Site Savings

+$4,950,060

Unlock Full NCT07632573 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07632573 Rescue Dossier →